Orexo Q2 FY26 net loss widens to SEK 102.5 million; revenue falls to SEK 3.5 million

• Orexo swung to a wider Q2 net loss of SEK 102.5 million, while net revenues fell 27.08% to SEK 3.5 million.
• Operating loss widened to SEK 103.3 million from SEK 85.3 million, while cash flow turned to an outflow of SEK 109.3 million.
• Cash and cash equivalents totaled SEK 276.9 million at quarter-end, including SEK 44.1 million payable to Dexcel.
• Izipry generated supportive stability data, keeping an NDA resubmission planned for Q3 2026 with potential FDA approval expected in Q1 2027.
• Orexo initiated a process with DNB Carnegie to evaluate additional financing while working to resolve the DOJ investigation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Orexo AB published the original content used to generate this news brief on July 16, 2026, and is solely responsible for the information contained therein.